mTOR inhibitors; PI3K/AKT/ mTOR pathway
By cancer
mTOR pathway inhibitors in breast cancer Breast cancer is the most commonly diagnosed cancer in women. The PI3K/AKT/ mTOR pathway is among the most frequently dysregulated pathways in patients with breast cancer. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential (...)
Home > A. Molecular pathology > Targeted therapy > Pathway-targeted therapy
Pathway-targeted therapy
Pathway-targeted therapeutics
-
mTOR pathway inhibitors
27 May 2017 -
PI3K pathway inhibitors
5 January 2014Open references
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP. Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi:10.1126/scitranslmed.3001065 . PMID: #20686178# (...) -
MAPK pathway inhibitors
5 January 2014MAPK pathway inhibitors
The MAPK pathway is a key therapeutic target for melanoma as it is activated in most tumors. Despite the clinical success of drugs targeting this pathway, their therapeutic efficacy is limited by the development of drug resistance. To develop effective therapies for melanoma, it is critical to uncover the mechanisms of resistance to BRAF inhibitors and MEK inhibitors. Recent studies on the molecular mechanisms of resistance to inhibitors of the MAPK pathway and (...) -
SHH pathway inhibitor
9 May 2012Hedgehog pathway inhibitor
References
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, Leblanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, Wainwright BJ, McGovern K, Olson JM. Proc Natl Acad Sci U S A. 2012 May 1. PMID: (...) -
pathway-targeted therapy of cancer
2 April 2012Pathway-targeted therapeutics of cancer
Substantial recent progress has been reported in the context of implementing ’personalized’ cancer medicine, informed by tumor genotyping.
The recent FDA approvals of crizotinib, an ALK kinase inhibitor that has yielded significant clinical benefit in ALK-translocated lung cancers, and vemurafenib, a BRAF-selective kinase inhibitor that has demonstrated dramatic clinical efficacy in BRAF mutant melanoma patients, define the new landscape for tailored (...) -
ERBB2-targeted therapy
23 November 2011HER2-targeted therapeutics, HER2-targeted therapy